Targets › ABCA1
3 programs from 3 companies in 3 trials: 1 Phase 3, 1 Phase 4, 1 Phase 2; Neurology, Metabolic and endocrine; next expected readout Apr 2027.
Catalyzes the translocation of specific phospholipids from the cytoplasmic to the extracellular/lumenal leaflet of membrane coupled to the hydrolysis of ATP. Thereby, participates in phospholipid transfer to apolipoproteins to form nascent high density lipoproteins/HDLs. Transports preferentially phosphatidylcholine over phosphatidylserine. (UniProt, O95477)
Open in Phaseline: the race on ABCA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| General Hospital of Shenyang Military Region | Probucol ATP-binding cassette sub-family A member 1 inhibitor | ABCA1 | Phase 4 | Stroke, Ischemic | Nov 2027 |
| First Affiliated Hospital of Wannan Medical College | Probucol ATP-binding cassette sub-family A member 1 inhibitor | ABCA1 | Phase 3 | Ischemic Stroke | Apr 2028 |
| River 3 Renal | R3R01 ATP-binding cassette transporter A1 (ABCA1) inducer that increases efflux of cholesterol f | ABCA1 | Phase 2 | Diabetic Kidney Disease | Apr 2027 |
Ischemic Stroke (1) Stroke, Ischemic (1) Diabetic Kidney Disease (1)
small molecule (3)
First Affiliated Hospital of Wannan Medical College (1) General Hospital of Shenyang Military Region (1) River 3 Renal (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.